

COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY 10213

Honorable Gaylord Nelson

-3-

February 27, 1974

purpose; however, without any supportive information or explanation from DOD, it is impossible to make a judgement that they do or do not serve a useful purpose. However, I would emphasize that at most, these represent a very few isolated incidences and that they probably total less than 2% of the so-called "additional requirements" listed by DOD in connection with the complete listing of NF items.

* * * * *

I trust these comments will be of assistance to you in your evaluation of the material submitted by DOD.

Sincerely,

Edward G. Feldmann, Ph.D.
Associate Executive Director
for Scientific Affairs

ehb

Enclosure